ly 353381 has been researched along with fulvestrant in 3 studies
Studies (ly 353381) | Trials (ly 353381) | Recent Studies (post-2010) (ly 353381) | Studies (fulvestrant) | Trials (fulvestrant) | Recent Studies (post-2010) (fulvestrant) |
---|---|---|---|---|---|
70 | 12 | 15 | 2,712 | 207 | 1,196 |
Protein | Taxonomy | ly 353381 (IC50) | fulvestrant (IC50) |
---|---|---|---|
Estrogen receptor | Homo sapiens (human) | 0.0061 | |
Estrogen receptor | Rattus norvegicus (Norway rat) | 0.0059 | |
Progesterone receptor | Homo sapiens (human) | 0.0002 | |
Steroid hormone receptor ERR1 | Homo sapiens (human) | 0.002 | |
Bifunctional epoxide hydrolase 2 | Homo sapiens (human) | 0.006 | |
Estrogen receptor beta | Homo sapiens (human) | 0.0104 | |
Bile acid receptor | Homo sapiens (human) | 0.79 | |
NAD-dependent protein deacylase sirtuin-5, mitochondrial | Homo sapiens (human) | 2.6 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aparicio, A; Bonnefous, C; Brigham, D; Darimont, B; Douglas, K; Govek, S; Grillot, K; Hager, JH; Heyman, R; Joseph, JD; Julien, J; Kahraman, M; Kaufman, J; Lai, A; Lee, KJ; Lu, N; Moon, MJ; Nagasawa, J; Prudente, R; Qian, J; Rix, PJ; Sensintaffar, J; Shao, G; Smith, ND | 1 |
Chan, S | 1 |
Christensen, GL; Freddie, CT; Lykkesfeldt, AE | 1 |
1 review(s) available for ly 353381 and fulvestrant
Article | Year |
---|---|
A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Piperidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes | 2002 |
2 other study(ies) available for ly 353381 and fulvestrant
Article | Year |
---|---|
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line, Tumor; Dogs; Drug Discovery; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Heterografts; Humans; Mice; Proteolysis; Rats; Selective Estrogen Receptor Modulators; Small Molecule Libraries; Tamoxifen | 2015 |
A new MCF-7 breast cancer cell line resistant to the arzoxifene metabolite desmethylarzoxifene.
Topics: Breast Neoplasms; Cathepsin D; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Fulvestrant; Histone Acetyltransferases; Humans; Nuclear Proteins; Nuclear Receptor Co-Repressor 1; Nuclear Receptor Coactivator 1; Piperidines; Proto-Oncogene Proteins c-bcl-2; Receptors, Progesterone; Repressor Proteins; RNA, Messenger; Tamoxifen; Thiophenes; Transcription Factors | 2004 |